| Dr Barbara Anita Clorey, PA-C | |
|
1350 Connecticut Ave Nw Ste 1250, Washington, DC 20036-1728 | |
| (202) 627-1901 | |
| Not Available |
| Full Name | Dr Barbara Anita Clorey |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 10 Years |
| Location | 1350 Connecticut Ave Nw Ste 1250, Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073607669 | NPI | - | NPPES |
| 470010400 | Medicaid | MD |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Centennial Medical Group, Pa | 2668466038 | 21 |
| First Call Medical Center Llc | 5496091290 | 29 |
News Archive
Researchers from Mount Sinai School of Medicine have identified a mechanism controlling the function of a protein that binds to DNA during embryonic development and may function to prevent abnormal tumor growth.
The impact of combat injury on intimacy is an important and often neglected aspect of healthcare communication. Four new fact sheets addressing the impact of the injuries of war, both physical and psychological, on intimacy have just been released for healthcare providers and affected military families.
The controversy around Merck and Co. Pharmaceuticals' pricing for its key AIDS drug Isentress — at nearly $13,000 per patient yearly, the most expensive first line AIDS therapy on the US market today — continued this week following Merck's reaction to recent public criticism of its AIDS drug pricing. Merck ramped up its damage control PR efforts, issuing a press release that sought to rewrite the history of Isentress and deflect attention by claiming AIDS Healthcare Foundation has been unfairly attacking them.
Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Barbara Anita Clorey, PA-C 1 Embarcadero Ctr Ste 1900, San Francisco, CA 94111-3723 Ph: (415) 658-6791 | Dr Barbara Anita Clorey, PA-C 1350 Connecticut Ave Nw Ste 1250, Washington, DC 20036-1728 Ph: (202) 627-1901 |
News Archive
Researchers from Mount Sinai School of Medicine have identified a mechanism controlling the function of a protein that binds to DNA during embryonic development and may function to prevent abnormal tumor growth.
The impact of combat injury on intimacy is an important and often neglected aspect of healthcare communication. Four new fact sheets addressing the impact of the injuries of war, both physical and psychological, on intimacy have just been released for healthcare providers and affected military families.
The controversy around Merck and Co. Pharmaceuticals' pricing for its key AIDS drug Isentress — at nearly $13,000 per patient yearly, the most expensive first line AIDS therapy on the US market today — continued this week following Merck's reaction to recent public criticism of its AIDS drug pricing. Merck ramped up its damage control PR efforts, issuing a press release that sought to rewrite the history of Isentress and deflect attention by claiming AIDS Healthcare Foundation has been unfairly attacking them.
Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body.
› Verified 4 days ago